CPTN DEADLINE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Cepton, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CPTN

New York, New York–(Newsfile Corp. – December 7, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers or sellers of common stock of Cepton, Inc. (NASDAQ: CPTN) between July 29, 2024 and January 6, 2025, both dates inclusive (the “Class Period”), of the important December 8, 2025 lead plaintiff deadline.

ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025

FOR IMMEDIATE RELEASE — ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025 — Updated clinical data presented at ASH show robust efficacy, rapid onset of remission, high incidence of MRD1-negativity, and an encouraging survival signal with ICT01 in combination with azacitidine and venetoclax (Aza-Ven) in newly

ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025

ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025 GlobeNewswire December 07, 2025 FOR IMMEDIATE RELEASE — ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025 — Updated clinical data presented at ASH show robust efficacy, rapid onset of

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease features A 12-day manufacturing time resulted in a vein-to-vein time

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting GlobeNewswire December 07, 2025 DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Blue Owl Capital Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OWL

New York, New York–(Newsfile Corp. – December 7, 2025) – Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Blue Owl Capital Inc. (NYSE: OWL) between February 6, 2025 and November 16, 2025. A class action lawsuit has already been filed. If you

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Alexandria Real Estate Equities, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ARE

New York, New York–(Newsfile Corp. – December 7, 2025) – Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Alexandria Real Estate Equities, Inc. (NYSE: ARE) between January 27, 2025 and October 27, 2025, both dates inclusive (the “Class Period”). A class action

ROSEN, A LEADING LAW FIRM, Encourages Perrigo Company plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – PRGO

New York, New York–(Newsfile Corp. – December 7, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Perrigo Company plc (NYSE: PRGO) between February 27, 2023 and November 4, 2025, both dates inclusive (the “Class Period”), of the important January 16, 2026 lead plaintiff deadline. SO WHAT:

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Inspire Medical Systems, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INSP

New York, New York–(Newsfile Corp. – December 7, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August 6, 2024 and August 4, 2025, both dates inclusive (the “Class Period”), of the important January 5, 2026 lead plaintiff deadline. SO

Scroll to Top